Breast Cancer Clinical Trial
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
PURPOSE: This phase II trial is studying how well radiation therapy works in treating older women who are undergoing surgery for invasive breast cancer.
Full Description
OBJECTIVES:
Primary
Determine the feasibility of intraoperative partial breast radiotherapy prior to surgical resection in older women with low-risk early stage primary invasive ductal carcinoma of the breast. Feasibility will be determined by the rate of good/excellent cosmesis, as measured by the Radiation Therapy Oncology Group (RTOG) cosmetic rating scale, in patients treated with this regimen compared with that of patients treated with partial breast brachytherapy in clinical trial RTOG-9517.
Determine the incidence of grade 3-4 toxicity of this regimen in these patients.
Determine the rate of ipsilateral breast recurrence, including recurrence within the tumor bed as compared to elsewhere in the breast, in patients treated with this regimen.
Secondary
Determine the radiation-induced activation of receptors and signal transduction pathways involved in radiation response in patients treated with this regimen.
OUTLINE: This is a non-randomized study.
Patients undergo intraoperative lymphatic mapping and sentinel lymphadenectomy OR standard level I, II axillary dissection to evaluate the lymph nodes followed by intraoperative breast ultrasonography to define the tumor target volume. Patients then undergo intraoperative single-dose partial breast radiotherapy followed by segmental mastectomy (i.e., lumpectomy) of the tumor. Patients with 1 or 2 tumor-involved surgical margins may undergo repeat segmental mastectomy. Patients with > 2 tumor-involved surgical margins undergo mastectomy. Patients determined to have a tumor size > 3 cm or an extensive intraductal component on final pathology evaluation undergo standard external beam radiotherapy after surgery.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2 to 3 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed primary invasive ductal carcinoma of the breast
Tumor size ≤ 3 cm
No extensive intraductal component
Tumor must not be attached to the skin, underlying muscle, or chest wall
Candidate for breast-conserving therapy, as determined by the surgical and radiation oncologist
Tumor amenable to segmental mastectomy (i.e., lumpectomy)
No bilateral breast cancer
No clinical or radiographic multifocal disease not amenable to single segmental mastectomy
Patients with > 1 tumor mass in the same breast must have only 1 mass that is histologically malignant AND all other masses must be proven histologically benign
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age
48 and over
Sex
Female
Menopausal status
Not specified
Performance status
0-2
Life expectancy
At least 5 years
Hematopoietic
Not specified
Hepatic
Not specified
Renal
Not specified
Other
Not pregnant
Fertile patients must use effective contraception
No collagen vascular disease
No medical condition that would preclude surgery
Other prior malignancy allowed provided the following criteria are met:
Patient has undergone potential curative therapy for all prior malignancies
There is no evidence of any prior malignancy within the past 5 years
Patient is deemed to be at low risk for recurrence of prior malignancy, as determined by the treating physician
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
No prior chemotherapy for this malignancy
Endocrine therapy
Not specified
Radiotherapy
No prior radiotherapy to the breast
Surgery
No breast implants
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chapel Hill North Carolina, 27599, United States
How clear is this clinincal trial information?